FDG PET/CT in Monitoring Very Early Therapy Response in Patients With Glioblastoma
| Status: | Recruiting |
|---|---|
| Conditions: | Brain Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - 99 |
| Updated: | 3/1/2019 |
| Start Date: | August 25, 2015 |
| End Date: | August 25, 2022 |
Very Early Response Monitoring in Patients With Glioblastoma Undergoing Therapy Using FDG PET/CT
This pilot clinical trial studies fluordeoxyglucose (fludeoxyglucose) F-18 (FDG) positron
emission tomography (PET)/computed tomography (CT) in monitoring very early therapy response
in patients with glioblastoma. Diagnostic procedures, such as FDG PET/CT, may help measure a
patient's response to earlier treatment. Chemotherapy can induce very rapid changes to the
tumor's glucose consumption which can be measured with imaging. FDG PET/CT shortly after the
start of therapy may help identify very early therapy response in patients with glioblastoma.
emission tomography (PET)/computed tomography (CT) in monitoring very early therapy response
in patients with glioblastoma. Diagnostic procedures, such as FDG PET/CT, may help measure a
patient's response to earlier treatment. Chemotherapy can induce very rapid changes to the
tumor's glucose consumption which can be measured with imaging. FDG PET/CT shortly after the
start of therapy may help identify very early therapy response in patients with glioblastoma.
PRIMARY OBJECTIVES:
I. To assess very early response to therapy in glioblastoma patients using 18F-FDG PET/CT.
II. Evaluate very early changes in FDG uptake within 48 hours of start of therapy and
correlate them with objective response parameters such as Response Assessment in
Neuro-Oncology (RANO) and survival.
OUTLINE:
Patients undergo standard FDG PET/CT scan 6-8 weeks before start of chemotherapy and one
additional FDG PET/CT scan within 48 hours of the start of chemotherapy.
I. To assess very early response to therapy in glioblastoma patients using 18F-FDG PET/CT.
II. Evaluate very early changes in FDG uptake within 48 hours of start of therapy and
correlate them with objective response parameters such as Response Assessment in
Neuro-Oncology (RANO) and survival.
OUTLINE:
Patients undergo standard FDG PET/CT scan 6-8 weeks before start of chemotherapy and one
additional FDG PET/CT scan within 48 hours of the start of chemotherapy.
Inclusion Criteria:
- Patients with histologically proven high grade glioma
- Intention to start therapy
Exclusion Criteria:
- Severe psychiatric illness
- Inability to give written consent
- Breast feeding / pregnancy
We found this trial at
1
site
Los Angeles, California 90095
Principal Investigator: Ken Herrmann
Phone: 310-825-7125
Click here to add this to my saved trials
